Revenue from operations grew by 19.12% year on year to Rs 2,118 crore in the quarter ended 30 June 2024.
Profit before tax for the quarter was at Rs 604 crore, up 22.76% from Rs 492 crore reported in the same period a year ago.
Total expense stood at Rs 1593 crore in Q1 FY25, up 16.53% on YoY basis. Cost of material consumed was at Rs 893 crore (up 7.72% YoY) and employee benefit expenses stood at Rs 292 crore (up 11.03% YoY) during the period under review.
Forex loss for the current quarter amounted to Rs 1 crore as against a gain of Rs 3 crore posted in Q1 FY24.
On standalone basis, the company’s net profit surged 24.64% to Rs 430 crore on 19.25% rise in revenue to Rs 2,063 crore in Q1 FY25 over Q1 FY24.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.
Shares of Divis Laboratories gained 1.40% to end at Rs 4,990.35 on Friday, 2 August 2024.